India is among the top global producers of economical vaccines, and generic medicines supplying in great volume with 20 percent of the total global demand. India has an established domestic pharmaceutical industry, with a wide network of 10,500 manufacturing units and 3000 drug companies.
The pharmaceutical industry in India manufactures wide-range of bulk drugs, which are the significant ingredients with medicinal properties that produce the basic raw materials for formulations.
Bulk drugs in the Pharmaceutical industry accounts roughly one-fifth of the industry output while rest for the formulations account. India also has the expertise for (APIs) active pharmaceutical ingredients and comprehends significant opportunities for value-creation.
According to the recent report, Indian supply over 80 percent of the anti-retroviral drugs used globally to combat Acquired Immuno Deficiency Syndrome (AIDS).
India’s current FDI (Foreign Direct Investment) policy permits 100 percent FDI in greenfield pharmaceutical projects under automatic route and up to 100 percent FDI in brownfield projects under government approval. Under the green field category, organizations establish supplementarily and began their own production by building new facilities or plants from the ground up.
Reckoned as a top-notch generic manufacturer globally, India exports more than 200 countries in the world that estimates around half of its total production of pharmaceuticals.